sarscov
first
emerg
novemb
guangdong
provinc
southern
part
china
spread
canada
singapor
vietnam
travel
hong
kong
hk
februari
march
novemb
unusu
epidem
atyp
pneumonia
foshan
guangdong
provinc
china
high
rate
nosocomi
transmiss
health
care
worker
hcw
retrospect
analysi
patient
hospit
atyp
pneumonia
guangzhou
januari
februari
reveal
posit
sarscov
nasopharyng
aspir
wherea
patient
posit
serolog
sarscov
convalesc
sera
genet
analysi
show
sarscov
isol
guangzhou
share
origin
countri
phylogenet
pathway
match
spread
sarscov
part
world
origin
viru
march
novel
cov
confirm
caus
agent
sar
thu
refer
sarscov
retrospect
serolog
survey
suggest
crossspeci
transmiss
sarscov
variant
anim
speci
human
might
occur
frequent
wet
market
high
seropreval
detect
among
asymptomat
anim
handler
initi
thought
mask
palm
civet
might
contribut
transmiss
sarscov
human
detect
close
variant
sarscov
palm
civet
dongmen
market
shenzhen
smallscal
sarscov
infect
outbreak
late
earli
china
patient
direct
indirect
contact
palm
civet
viral
genom
sequenc
analysi
show
howev
sarscovlik
viru
present
among
mask
civet
market
long
cov
highli
similar
sarscov
isol
horsesho
bat
bat
sarslik
cov
share
sequenc
homolog
human
civet
isol
data
suggest
bat
could
natur
reservoir
close
ancestor
sarscov
pathogenesi
sarscov
infect
human
respiratori
tract
mainli
via
droplet
transmiss
although
human
intestin
cell
prove
suscept
sarscov
replic
role
intestin
tract
portal
entri
remain
uncertain
surfac
envelop
spike
protein
protein
sarscov
play
import
role
establish
infect
determin
cell
tissu
tropism
entri
viru
requir
receptor
bind
follow
conform
chang
protein
cathepsin
lmediat
proteolysi
within
endosom
angiotensinconvert
enzym
host
receptor
mediat
entri
sarscov
express
wide
varieti
bodi
tissu
sever
mechan
direct
injuri
infect
lung
sar
reveal
probabl
contribut
diffus
alveolar
damag
dad
neg
regul
local
reninangiotensin
system
data
anim
studi
support
dad
seen
sar
mediat
pathway
addit
sarscovencod
protein
shown
strong
induc
apoptosi
cell
line
deriv
differ
organ
includ
lung
kidney
liver
activ
helper
cellmedi
immun
hyperinn
inflammatori
respons
might
respons
diseas
progress
sarscov
infect
shown
mark
increas
level
inflammatori
cytokin
ifng
interleukin
il
mark
increas
chemokin
chemokin
ifnginduc
protein
neutrophil
chemokin
monocyt
chemoattract
patient
sarscov
infect
day
ill
onset
mice
infect
sarscov
cell
play
import
role
sarscov
clearanc
wherea
reduc
tcell
respons
contribut
sever
diseas
anoth
studi
mice
infect
sarscov
robust
viru
replic
accompani
delay
type
ifn
ifni
signal
observ
orchestr
inflammatori
respons
lung
immunopatholog
reduc
surviv
casecontrol
studi
suggest
genet
variant
receptor
predispos
sarscov
infect
wherea
mannosebind
lectin
defici
suscept
factor
acquisit
sarscov
infect
lung
histopatholog
patient
sever
sarscov
infect
includ
dad
denud
bronchial
epithelia
loss
cilia
squamou
metaplasia
giant
cell
infiltr
mark
increas
macrophag
alveoli
interstitium
hemophagocytosi
atrophi
white
pulp
spleen
hyalin
membran
secondari
bacteri
pneumonia
also
note
although
dad
main
pulmonari
featur
lesion
subpleur
locat
resembl
bronchiol
obliteran
organ
pneumonia
also
seen
epidemiolog
nephrologist
came
southern
china
hk
februari
index
case
caus
subsequ
outbreak
sarscov
infect
hk
singapor
toronto
sixteen
hotel
guestsvisitor
infect
physician
stay
visit
friend
floor
hotel
physician
stay
intern
air
travel
visitor
spread
infect
countriesregion
total
case
mortal
rate
end
epidem
juli
sar
seem
spread
close
persontoperson
contact
via
droplet
transmiss
contact
fomit
superspread
event
hallmark
sarscov
infect
reflect
nosocomi
outbreak
major
teach
hospit
hk
subject
mani
hcw
previous
healthi
infect
within
week
exposur
patient
visitor
hotel
hospit
communityacquir
pneumonia
gener
medic
ward
superspread
event
like
caus
sever
factor
includ
use
jet
nebul
deliv
bronchodil
index
case
overcrowd
poor
ventil
hospit
ward
addit
temporalspati
spread
sarscov
among
inpati
index
medic
ward
hospit
hk
consist
airborn
transmiss
apart
respiratori
secret
sarscov
detect
fece
urin
tear
infect
individu
addit
sarscov
might
spread
opportunist
airborn
transmiss
major
commun
outbreak
involv
resid
privat
residenti
complex
amoy
garden
hk
dri
water
insid
ushap
bathroom
floor
drain
backflow
contamin
sewag
sar
patient
renal
failur
diarrhea
relat
neg
pressur
gener
toilet
exhaust
fan
might
creat
infecti
aerosol
move
upward
warm
airshaft
build
base
analysi
distribut
confirm
case
airborn
spread
like
explan
amoy
garden
outbreak
sarscov
could
spread
nearbi
residenti
complex
air
sampl
obtain
hospit
room
toronto
occupi
sar
patient
swab
sampl
taken
frequent
touch
surfac
room
nurs
station
toronto
posit
pcr
test
data
suggest
possibl
airborn
transmiss
stress
import
take
appropri
respiratori
protect
apart
strict
surfac
hygien
practic
estim
mean
incub
period
sar
day
ci
day
wherea
mean
time
symptom
onset
hospit
vari
day
day
decreas
cours
epidem
mean
time
onset
death
day
ci
day
major
clinic
featur
sarscov
infect
present
includ
persist
fever
chillsrigor
myalgia
dri
cough
headach
malais
dyspnea
sore
throat
rhinorrhea
sputum
product
nausea
vomit
dizzi
less
common
wateri
diarrhea
becam
promin
patient
sar
one
week
ill
onset
clinic
cours
ill
patient
present
statu
epilepticu
sarscov
detect
cerebrospin
fluid
serum
sampl
elderli
subject
might
develop
fever
present
decreas
gener
condit
delirium
poor
feed
fallfractur
teenag
tend
follow
clinic
cours
similar
adult
wherea
young
children
year
age
often
ran
benign
clinic
cours
report
fatal
young
children
teenag
patient
sar
pregnanc
carri
signific
risk
mortal
asymptomat
infect
seem
uncommon
metaanalysi
shown
overal
seropreval
rate
gener
popul
hcw
although
true
incid
asymptomat
infect
remain
unknown
typic
pattern
clinic
cours
sar
phase
viral
replic
associ
increas
sarscov
load
character
fever
myalgia
system
symptom
gener
improv
day
phase
immunopatholog
injuri
character
recurr
fever
hypoxemia
radiolog
progress
pneumonia
fall
viral
load
wherea
approxim
patient
progress
acut
respiratori
distress
syndrom
ard
necessit
invas
mechan
ventilatori
support
peak
viral
load
day
ill
follow
progress
decreas
rate
viral
shed
nasopharynx
stool
urin
day
day
symptom
onset
clinic
worsen
phase
like
result
immunemedi
lung
injuri
due
overexuber
host
respons
lymphopenia
dissemin
intravascular
coagul
elev
lactat
dehydrogenas
creatinin
kinas
common
laboratori
featur
sar
tlymphocyt
count
fell
earli
cours
sar
wherea
low
count
present
associ
advers
clinic
outcom
although
nonspecif
common
radiograph
featur
sar
includ
predomin
involv
lung
peripheri
lower
zone
addit
absenc
cavit
hilar
lymphadenopathi
pleural
effus
radiograph
progress
unilater
focal
airspac
opac
either
multifoc
bilater
involv
occur
second
phase
diseas
follow
radiograph
improv
treatment
case
seri
spontan
pneumomediastinum
occur
patient
wherea
patient
develop
ard
period
week
common
highresolut
ct
featur
includ
groundglass
opacif
sometim
consolid
interlobular
septal
intralobular
interstiti
thicken
predominantli
peripher
lower
lobe
involv
treatment
ribavirin
nucleosid
analog
wide
use
treat
sar
patient
ribavirin
alon
signific
vitro
activ
sarscov
caus
signific
hemolysi
mani
patient
lopinavir
ritonavir
combin
boost
proteas
inhibitor
regimen
wide
use
treatment
hiv
infect
vitro
activ
sarscov
demonstr
lopinavir
ribavirin
mgml
mgml
respect
wherea
inhibit
vitro
cytopath
effect
achiev
concentr
mgml
lopinavir
combin
mgml
ribavirin
retrospect
analysi
show
addit
lopinavir
mg
ritonavir
mg
initi
therapi
associ
lower
overal
death
rate
vs
intub
rate
vs
match
histor
cohort
receiv
ribavirin
alon
initi
antivir
therapi
outcom
subgroup
receiv
lopinavirritonavir
late
rescu
therapi
receiv
puls
methylprednisolon
worsen
respiratori
symptom
howev
better
match
cohort
ifni
produc
earli
part
innat
immun
respons
viru
infect
vitro
limit
anim
observ
data
ifn
particular
earli
use
efficaci
sarscov
experiment
infect
cynomolgu
macaqu
prophylact
treatment
pegyl
ifna
significantli
reduc
viral
replic
excret
viral
antigen
ag
express
type
pneumocyt
lung
damag
versu
untreat
macaqu
wherea
postexposur
treatment
pegyl
ifna
yield
intermedi
result
use
plu
system
corticosteroid
associ
improv
oxygen
satur
rapid
resolut
radiograph
lung
opac
lower
level
creatinin
kinas
system
corticosteroid
alon
anoth
studi
sar
patient
second
week
sar
ill
evid
bronchiol
obliteran
organ
pneumonia
radiolog
histopatholog
case
wherea
progress
pulmonari
diseas
mediat
host
inflammatori
respons
system
corticosteroid
form
puls
methylprednisolon
significantli
reduc
concentr
day
treatment
adult
sar
patient
uncontrol
studi
induct
thought
critic
event
initi
immunemedi
lung
injuri
lymphocyt
apoptosi
use
rescu
puls
methylprednisolon
clinic
progress
associ
favor
clinic
improv
patient
resolut
fever
radiograph
lung
opac
within
week
retrospect
analysi
show
howev
theus
puls
methylprednisolon
associ
increas
risk
mortal
adjust
odd
ratio
ci
addit
dissemin
fungal
diseas
avascular
osteonecrosi
occur
prolong
system
corticosteroid
therapi
random
placebocontrol
studi
show
plasma
sarscov
rna
concentr
second
third
week
ill
higher
patient
given
initi
hydrocortison
n
intraven
given
normal
salin
control
n
earli
clinic
cours
ill
despit
small
sampl
size
data
suggest
system
corticosteroid
given
earlier
phase
might
prolong
viremia
convalesc
plasma
donat
patient
includ
hcw
recov
sar
contain
high
level
neutral
antibodi
seem
clinic
use
treat
sar
patient
studi
compar
patient
sarscov
infect
receiv
convalesc
plasma
patient
receiv
therapi
better
surviv
rate
vs
discharg
rate
vs
compar
control
among
nonrandom
patient
sar
given
convalesc
plasma
princ
wale
hospit
shatin
hong
kong
discharg
rate
day
patient
n
treat
within
day
ill
onset
versu
n
treat
beyond
day
exploratori
post
hoc
metaanalysi
studi
sarscov
infect
sever
influenza
show
signific
reduct
pool
odd
mortal
convalesc
plasma
versu
placebo
treatment
ci
casecontrol
studi
involv
medic
ward
hospit
hk
guangzhou
identifi
independ
factor
superspread
nosocomi
outbreak
sarscov
infect
perform
resuscit
minimum
distanc
bed
less
staff
work
experi
symptom
sar
patient
requir
oxygen
therapi
noninvas
ventil
wherea
avail
wash
chang
facil
staff
protect
factor
box
systemat
review
shown
aerosolgener
procedur
would
increas
risk
nosocomi
sar
transmiss
hcw
includ
tracheal
intub
noninvas
ventil
tracheotomi
manual
ventil
intub
box
thu
import
hcw
take
airborn
precaut
carri
aerosolgener
procedur
merscov
first
report
septemb
novel
bcov
isol
male
patient
die
sever
pneumonia
multiorgan
failur
saudi
arabia
june
merscov
infect
spread
countri
sinc
discoveri
global
septemb
june
world
health
organ
inform
laboratoryconfirm
case
infect
merscov
least
death
case
definit
suspect
confirm
case
merscov
infect
shown
box
although
natur
reservoir
merscov
still
unclear
bat
may
one
possibl
reservoir
viru
studi
screen
fecal
specimen
bat
ghana
european
countri
bcov
virus
relat
novel
human
bcov
emc
later
renam
merscov
detect
nycteri
bat
pipistrellu
bat
bat
sampl
test
anoth
studi
fragment
merscov
found
taphoz
bat
close
match
human
isol
merscov
genet
related
indic
merscov
origin
bat
dromedari
camel
import
natur
host
mainten
diversif
epidemiolog
link
may
occur
within
period
onset
ill
case
consider
inadequ
specimen
would
includ
nasopharyng
swab
without
accompani
lower
respiratori
specimen
specimen
improp
handl
judg
poor
qualiti
test
laboratori
taken
late
cours
ill
posit
screen
test
singl
rrtpcr
target
without
confirm
evid
seroreact
singl
convalesc
serum
sampl
ideal
taken
least
day
exposur
screen
assay
elisa
immunofluoresc
assay
neutral
assay
absenc
molecular
confirm
respiratori
specimen
merscov
seem
major
sourc
zoonot
human
infect
viru
isol
dromedari
camel
arabian
peninsula
across
north
africa
east
africa
west
africa
central
africa
found
dromedari
camel
kazakhstan
bactrian
camel
mongolia
countri
minor
report
mer
human
case
howev
report
direct
camel
exposur
epidemiolog
although
merscov
first
describ
septemb
retrospect
analysi
cluster
hospit
case
date
back
april
jordan
confirm
merscov
rtpcr
serolog
etiolog
outbreak
involv
least
hcw
epidemiolog
merscov
character
sporad
zoonot
transmiss
event
sometim
follow
nosocomi
outbreak
within
health
care
set
due
failur
infect
control
prevent
measur
saudi
arabia
largest
merscov
caseload
follow
south
korea
countri
highest
caseload
outsid
arab
peninsula
risk
factor
primari
merscov
infect
address
casecontrol
studi
consist
primari
merscov
case
report
march
novemb
saudi
arabia
control
match
age
gender
neighborhood
case
patient
use
multivari
analysi
investig
demonstr
direct
dromedari
exposur
week
ill
onset
strongli
associ
merscov
ill
adjust
ci
along
diabet
mellitu
adjust
ci
heart
diseas
adjust
ci
current
tobacco
smoke
adjust
ci
risk
secondari
transmiss
patient
household
contact
estim
approxim
risk
factor
household
transmiss
includ
sleep
index
patient
room
touch
respiratori
secret
index
patient
wherea
casual
contact
simpl
proxim
associ
transmiss
crosssect
serosurveil
studi
healthi
individu
saudi
arabia
evid
posit
merscov
serolog
suggest
number
mild
asymptomat
infect
far
exce
recogn
seroposit
common
men
women
central
coastal
provinc
camel
shepherd
slaughterhous
worker
gener
popul
nosocomi
transmiss
hallmark
merscov
infect
superspread
event
merscov
infect
report
jordan
al
hasa
jeddah
abu
dhabi
wherea
major
outbreak
south
korea
character
sever
superspread
event
hospit
set
failur
infect
control
prevent
health
care
facil
hcf
result
larg
number
secondari
case
merscov
infect
involv
hcw
exist
patient
visitor
saudi
arabia
sever
countri
past
year
common
predispos
factor
includ
exposur
contamin
overcrowd
hcf
poor
complianc
appropri
person
protect
equip
ppe
assess
patient
febril
respiratori
ill
applic
potenti
aerosolgener
procedur
resuscit
continu
posit
airway
pressur
nebul
medic
lack
proper
isol
room
facil
custom
patient
seek
care
differ
hcf
doctor
shop
friend
famili
member
stay
patient
caregiv
alreadi
overcrowd
hcf
uniqu
factor
south
korea
contrast
sar
approxim
patient
mer
least
comorbid
ill
wherea
fatal
case
like
underli
condit
among
fatal
case
vs
among
recov
asymptomat
case
p
indexsporad
case
older
median
age
year
vs
year
p
like
suffer
sever
diseas
requir
hospit
vs
p
comparison
secondari
case
case
specif
report
mild
diseas
asymptomat
occur
among
secondari
case
index
sporad
case
sever
diseas
wherea
higher
proport
patient
renal
failur
note
among
secondari
case
saudi
arabia
due
nosocomi
outbreak
involv
hemodialysi
unit
hospit
al
hasa
good
infect
control
measur
report
cluster
involv
hc
probabl
limit
onward
transmiss
hcw
hospit
patient
clinic
present
merscov
infect
rang
asymptomat
sever
pneumonia
ard
septic
shock
multiorgan
failur
result
death
contrast
sar
clinic
cours
mer
sever
immunocompromis
patient
gener
mild
individu
without
comorbid
ill
case
report
children
less
year
age
typic
merscov
infect
begin
fever
cough
chill
sore
throat
myalgia
arthralgia
follow
dyspnea
rapid
progress
pneumonia
within
first
week
contrast
sar
often
requir
ventilatori
organ
support
patient
present
respiratori
ill
although
immunocompromis
patient
may
present
fever
chill
diarrhea
develop
pneumonia
due
merscov
least
onethird
patient
also
gastrointestin
symptom
vomit
diarrhea
neurolog
complic
intracerebr
hemorrhag
due
thrombocytopenia
dissemin
intravascular
coagul
platelet
dysfunct
critic
ill
polyneuropathi
complic
long
icu
stay
report
pregnant
women
infect
mer
may
develop
sever
diseas
fatal
outcom
includ
stillbirth
concomit
infect
low
albumin
found
predictor
sever
infect
wherea
age
greater
equal
year
predictor
increas
mortal
base
data
relat
humantohuman
transmiss
sever
cluster
incub
period
estim
day
could
long
week
median
day
ci
median
time
symptom
onset
mer
hospit
admiss
icu
death
rang
n
n
day
n
respect
similar
sar
sever
viral
ill
common
laboratori
find
mer
includ
leukopenia
particular
lymphopenia
report
sever
case
found
viral
rna
blood
urin
stool
much
lower
viral
load
respiratori
tract
viral
load
upper
respiratori
tract
specimen
gener
lower
lower
respiratori
specimen
radiograph
find
mer
consist
viral
pneumon
ard
bilater
hilar
infiltr
unilater
bilater
patchi
densiti
infiltr
segment
lobar
opac
groundglass
opac
small
pleural
effus
case
lower
lobe
affect
upper
lobe
earli
cours
ill
rapid
radiograph
progress
sar
common
ct
find
hospit
patient
merscov
infect
bilater
predominantli
subpleur
basilar
airspac
chang
extens
groundglass
opac
consolid
subpleur
peribronchovascular
predilect
abnorm
suggest
organ
pneumonia
pattern
dipeptidyl
peptidas
also
known
identifi
function
cellular
receptor
merscov
homologu
permit
merscov
infect
present
varieti
cell
line
cellbas
studi
reveal
merscov
evad
innat
immun
respons
may
explain
larg
number
sever
case
widespread
merscov
ag
express
observ
type
type
ii
alveolar
cell
ciliat
bronchial
epithelium
uncili
cuboid
cell
termin
bronchiol
viru
ag
also
found
endotheli
cell
pulmonari
vessel
rare
alveolar
macrophag
contrast
patient
surviv
nosocomi
merscov
infect
franc
index
patient
fatal
outcom
promot
type
ifn
especi
ifna
respons
merscov
level
mediat
ifng
promot
viral
clearanc
much
lower
fatal
case
patient
surviv
lower
respiratori
tract
lrt
excret
merscov
could
observ
month
sever
ill
patient
present
express
viru
blood
urin
consist
impair
type
ifnmedi
immunolog
respons
index
patient
respons
develop
patient
surviv
studi
adult
patient
infect
merscov
saudi
arabia
viral
load
much
higher
lrt
specimen
upper
respiratori
tract
serum
sampl
test
yield
viral
rna
wherea
stool
urin
sampl
yield
viral
rna
seroconvers
occur
first
week
diagnosi
correspond
second
third
week
symptom
onset
surviv
patient
slightli
half
fatal
case
produc
igg
neutral
antibodi
level
igg
neutral
antibodi
weakli
invers
correl
lrt
viral
load
presenc
antibodi
lead
elimin
viru
lrt
patient
south
korea
robust
antibodi
respons
develop
third
week
ill
wherea
delay
antibodi
respons
neutral
test
associ
sever
diseas
merscov
antibodi
includ
neutral
antibodi
detect
person
serolog
posit
indetermin
least
month
nosocomi
outbreak
jordan
autopsi
yearold
man
die
merscov
infect
abu
dhabi
reveal
dad
pneumocyt
epitheli
syncyti
cell
import
target
merscov
ag
receptor
found
scatter
pneumocyt
syncyti
cell
evid
extrapulmonari
merscov
ag
detect
includ
kidney
renal
biopsi
perform
week
onset
symptom
patient
infect
merscov
infect
south
korea
acut
tubular
necrosi
main
find
wherea
proteinac
cast
format
acut
tubuleinterstiti
nephriti
found
electron
dens
deposit
observ
electron
microscopi
investig
could
verifi
viru
situ
hybrid
confoc
microscopi
merscov
costain
treatment
merscov
caus
cytokin
chemokin
dysregul
induc
significantli
higher
express
level
cytokin
ifng
chemokin
motif
chemokin
ligand
motif
chemokin
ligand
major
intrins
protein
mip
sarscov
human
monocytederiv
macrophag
host
innat
ifn
respons
crucial
control
viral
replic
infect
absenc
ifna
impair
develop
robust
antivir
adapt
immun
respons
mediat
ifng
promot
viral
clearanc
bring
substanti
argument
indic
earli
ifna
treatment
merscov
infect
mani
compound
found
vitro
inhibitori
activ
merscov
infect
notabl
type
ifn
ifnb
show
strongest
inhibitori
activ
wherea
ribavirin
combin
superior
individu
compon
reduc
merscov
viral
load
vero
cell
rhesu
macaqu
infect
merscov
combin
therapi
high
dose
ribavirin
modestli
reduc
viral
titer
measur
lung
injuri
observ
studi
clinic
use
report
inconsist
find
small
case
seri
show
mortal
patient
receiv
plu
ribavirin
administ
median
day
rang
day
admiss
studi
patient
compar
outcom
patient
treat
mg
subcutan
weekli
combin
ribavirin
load
dose
g
oral
follow
mg
oral
everi
h
versu
patient
treat
mg
subcutan
time
weekli
combin
ribavirin
found
high
mortal
group
signific
differ
versu
p
although
earlier
studi
patient
treat
combin
ribavirin
found
improv
surviv
rate
day
favor
find
longer
signific
day
mortal
vs
compar
group
untreat
patient
confirm
merscov
infect
p
investig
attribut
lack
effect
older
age
presenc
comorbid
condit
delay
treatment
initi
one
case
studi
describ
use
lopinavir
part
tripletherapi
regimen
combin
ifn
ribavirin
merscov
infect
patient
subsequ
die
greec
despit
initi
resolut
viraemia
nitazoxanid
anoth
potent
type
ifn
induc
use
human
parasit
infect
synthet
nitrothiazolylsalicylamid
deriv
exhibit
broadspectrum
antivir
activ
rna
dna
virus
includ
canin
cov
influenza
virus
hepat
b
viru
hepat
c
viru
hiv
rotaviru
noroviru
flavivirus
combin
use
ifn
induc
eg
nitazoxanid
chloroquin
innat
immunomodul
effect
antivir
agent
may
synergist
evalu
anim
model
system
corticosteroid
use
empir
patient
merscov
infect
dampen
immunopatholog
host
respons
surviv
benefit
report
comprehens
review
shown
use
system
corticosteroid
patient
sever
influenza
infect
associ
increas
risk
nosocomi
pneumonia
higher
mortal
longer
length
stay
system
corticosteroid
use
cautious
use
associ
worsen
outcom
patient
infect
sarscov
epidem
includ
fatal
aspergillosi
osteonecrosi
nucleosidesnucleotid
build
block
viral
nucleic
acid
drug
target
nucleosidesnucleotid
andor
viral
nucleic
acid
gener
broadspectrum
activ
wide
rang
cov
virus
mycophenol
mofetil
antireject
drug
inhibit
inosin
monophosph
dehydrogenas
guanin
monophosph
synthesi
activ
compound
mycophenol
acid
exhibit
antivir
activ
vitro
variou
virus
includ
hepat
b
viru
hepat
c
viru
arbovirus
mycophenol
acid
identifi
potenti
antimerscov
drug
use
highthroughput
screen
exhibit
potent
antimerscov
activ
vitro
vitro
activ
howev
necessarili
translat
vivo
effect
followup
studi
group
investig
shown
merscovinfect
common
marmoset
treat
mycophenol
mofetil
worsen
outcom
sever
diseas
higher
viral
load
necropsi
lung
extrapulmonari
tissu
compar
untreat
anim
renal
transplant
recipi
mainten
mycophenol
mofetil
therapi
also
develop
sever
fatal
merscov
infect
thu
usual
dosag
mycophenol
mofetil
monotherapi
unlik
use
either
prophylaxi
treatment
cov
infect
systemat
review
exploratori
metaanalysi
patient
sarscov
influenza
viru
treat
convalesc
plasma
show
reduct
mortal
thu
consid
potenti
treatment
mercov
infect
convalesc
plasma
patient
fulli
recov
merscov
infect
welldefin
level
merscov
neutral
antibodi
howev
readili
avail
limit
factor
appropri
window
period
plasma
retriev
suitabl
donor
time
administr
ill
patient
merscov
infect
addit
concern
treatment
dose
may
result
undesir
volum
expans
patient
ard
requir
fluid
restrict
variou
monoclon
polyclon
antibodi
prepar
neutral
activ
inhibit
merscov
preclin
model
publish
human
data
howev
date
use
prepar
convalesc
plasma
treatment
patient
merscov
infect
although
concern
challeng
marmoset
merscov
may
consist
lead
sever
diseas
marmoset
model
data
need
suitabl
anim
studi
care
conduct
clinic
virolog
studi
prioriti
treatment
convalesc
plasma
ifn
ideal
random
clinic
trial
suffici
number
patient
avail
present
clinic
manag
patient
sever
diseas
larg
reli
meticul
icu
support
prevent
complic
feasibl
clinic
trial
option
present
includ
monotherapi
combin
therapi
lopinavirritonavir
passiv
immunotherapi
convalesc
plasma
human
monoclon
polyclon
antibodi
clinic
trial
data
need
assess
role
ifn
ribavirin
combin
nitazoxanid
chloroquin
wherea
system
corticosteroid
ribavirin
monotherapi
intraven
gammaglobulin
mycophenol
acid
would
pose
harm
benefit
box
bat
seem
common
natur
sourc
sarscov
merscov
clinic
featur
similar
mer
progress
respiratori
failur
much
rapidli
sar
although
estim
pandem
potenti
merscov
lower
sarscov
case
fatal
rate
mer
much
higher
like
relat
older
age
comorbid
ill
sporad
case
lot
knowledg
gap
remain
sinc
first
discoveri
merscov
studi
need
understand
pathogenesi
viral
kinet
mode
diseas
transmiss
intermediari
sourc
merscov
guid
public
health
infect
control
measur
treatment
also
import
watch
emerg
mutat
sarslik
cluster
circul
cov
bat
popul
may
threaten
human
health
